Treatment of High-grade Non–muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial “NIMBUS”
Marc‐Oliver Grimm(Jena University Hospital), E. Mumperow, Sarah Bos, Mario W. Kramer, Jörg Klier, Thomas Pulte, Harm H.E. van Melick, Holger Schreier, Anders Bjartell(Malmö University), Luis Martínez‐Piñeiro(Hospital Universitario La Paz), Marc Colombel(Hôpital Edouard Herriot), Christien Caris(European Association of Urology), E. Boven, Jan Marin, Dirk Zaak, Joan Palou(Puigvert Foundation), Richard P. Meijer(University Medical Center Utrecht), Tim Muilwijk(KU Leuven), Michael Stephan-Odenthal, S. Machtens, Antoine G. van der Heijden(Radboud University Nijmegen), Bernd J. Schmitz‐Dräger, Andreas Schneider, Gerd Rodemer, Marie L. De Bruin, Eva Hellmis, Anup Patel, Jörg Horstmann, Manfred P. Wirth(University Hospital Carl Gustav Carus), Wim P.J. Witjes(European Association of Urology), T. De Reijke, R. van Moorselaar, Roger Zillmann, T. Werner, Raymond G. Schipper(European Association of Urology), Joost L. Boormans(Erasmus MC), Georgios Gakis(University of Würzburg), Spiegelhalder, Andreas Al Ghazal, Levent N. Türkeri(Acıbadem University), Robert H. Rudolph, Marko Babjuk(Charles University), Wolfgang Rulf, Bart P. Wijsman, Theodor Klotz, Michael Siebels, H. Suttmann
Cited by 132
Related Papers
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)
|The Lancet|2012|864
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|618
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)
|World Journal of Urology|2016|471